ImmuPharma is a London-based biopharmaceutical company that specializes in peptide-based therapeutics for a range of therapy areas, including autoimmunity, metabolism, anti-infectives, and cancer. The company's lead product candidate is Lupuzor, which is designed to treat lupus, an autoimmune chronic inflammatory disease, and is currently in Phase III clinical trials. ImmuPharma also has other product candidates, including IPP-204106, a peptide for modulating angiogenesis with applications in cancer and ophthalmology, and BioGlucagon, a therapy for low sugar events in diabetes. The company has collaboration arrangements with Centre National de la Recherche Scientifique and Avion Pharmaceuticals LLC for the development and licensing of peptide technology and products. ImmuPharma was founded in 1999.